Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Eribulin in BRAF V600E-mutant metastatic colorectal cancer: case series and potential rationale.

Annals of oncology : official journal of the European Society for Medical Oncology - 1 May 2018

Masuishi T, Taniguchi H, Sugiyama K, Kato K, Mitani S, Honda K, Narita Y, Kadowaki S, Ura T, Ando M, Muro K

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ATP Binding Cassette Transporter, Subfamily B
Share to CA-19-9 Antigen
Share to Fatal Outcome

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Furans

Share to Ketones

Share to Mitosis

Share to Tomography, X-Ray Computed

Share to Tumor Burden

Source

Identifiers

PMID: 29635451
DOI: 10.1093/annonc/mdy107

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Eribulin in BRAF V600E-mutant metastatic colorectal cancer: case series and potential rationale.PMID 29635451Read ↗

Rationale and design of the BRAVERY study (EPOC1701): a multicentre phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer.Semantic proximity Read ↗

Dramatic response to encorafenib in a patient with Erdheim-Chester disease harboring the BRAFV600E mutation.Semantic proximity Read ↗

Cases in the management of metastatic colorectal cancer: regorafenib as second-line therapy after FOLFOXIRI plus bevacizumab in a patient with a KRAS mutation.Semantic proximity Read ↗

Unexpected and durable response with regorafenib in a metastatic colorectal cancer patient without KDR mutation: A case report.Semantic proximity Read ↗

Cases in the management of metastatic colorectal cancer: sequencing therapies in a patient with the BRAF V600E mutation.Semantic proximity Read ↗

Treatment with encorafenib and cetuximab of a non-anti-epidermal growth factor receptor-naive patient for BRAF V600E-mutated metastatic colon cancer.Semantic proximity Read ↗

Durable Disease Control with Regorafenib in a Patient with Metastatic KIT-Mutated Colorectal Cancer.Semantic proximity Read ↗

[Bevacizumab in the treatment of colorectal carcinoma: news from ASCO 2008].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.